IgG EPITOPE AND APPLICATIONS THEREOF AS A DRUG TARGET
AssigneeGuangzhou Sig Biopharmaceutical Technology Co., Ltd.
InventorsXiaoyan QIU, Jingshu TANG, Shenghua ZHANG, Wenhua JIANG, Zhiqiao HE
Life of this patent
Estimating the term…
Loading patent…
AssigneeGuangzhou Sig Biopharmaceutical Technology Co., Ltd.
InventorsXiaoyan QIU, Jingshu TANG, Shenghua ZHANG, Wenhua JIANG, Zhiqiao HE
Estimating the term…
IgG epitope and applications thereof as a target are provided. The IgG epitope is the CH1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin β4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.
An isolated immunogenic peptide, wherein the immunogenic peptide comprises the amino acid sequence as shown in SEQ ID NO:
Dependencies are inferred from the claim text.